Moderna, Inc. (NASDAQ:MRNA) CEO Sells $4,990,000.00 in Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $124.75, for a total transaction of $4,990,000.00. Following the completion of the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at approximately $675,140,263.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Stephane Bancel also recently made the following trade(s):

  • On Thursday, September 15th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $137.11, for a total transaction of $5,484,400.00.
  • On Wednesday, September 7th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $133.68, for a total transaction of $5,347,200.00.
  • On Wednesday, August 24th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $142.21, for a total transaction of $5,688,400.00.
  • On Wednesday, August 17th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $159.03, for a total transaction of $6,361,200.00.
  • On Wednesday, August 10th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $172.29, for a total transaction of $6,891,600.00.
  • On Thursday, August 4th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $192.94, for a total transaction of $7,717,600.00.
  • On Thursday, July 28th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $156.73, for a total transaction of $6,269,200.00.
  • On Thursday, July 21st, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $168.11, for a total transaction of $6,724,400.00.
  • On Wednesday, July 13th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $172.69, for a total transaction of $6,907,600.00.
  • On Thursday, July 7th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $171.00, for a total transaction of $6,840,000.00.

Moderna Price Performance

MRNA stock traded down $0.68 during trading on Friday, hitting $123.64. The company had a trading volume of 3,846,408 shares, compared to its average volume of 6,482,469. The firm has a market capitalization of $49.18 billion, a price-to-earnings ratio of 3.72, a P/E/G ratio of 0.73 and a beta of 1.69. The business has a 50 day moving average of $152.65 and a 200 day moving average of $150.76. Moderna, Inc. has a fifty-two week low of $115.61 and a fifty-two week high of $453.61. The company has a current ratio of 1.99, a quick ratio of 1.71 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNAGet Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 earnings per share for the quarter, topping the consensus estimate of $4.73 by $0.51. The business had revenue of $4.73 billion during the quarter, compared to the consensus estimate of $3.95 billion. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.46 earnings per share. As a group, research analysts predict that Moderna, Inc. will post 26.41 earnings per share for the current year.

Institutional Investors Weigh In On Moderna

A number of institutional investors and hedge funds have recently bought and sold shares of MRNA. People s United Financial Inc. lifted its holdings in Moderna by 52.4% in the 4th quarter. People s United Financial Inc. now owns 3,534 shares of the company’s stock valued at $898,000 after acquiring an additional 1,215 shares during the last quarter. Rockefeller Capital Management L.P. lifted its holdings in Moderna by 5.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 23,789 shares of the company’s stock valued at $6,041,000 after acquiring an additional 1,305 shares during the last quarter. Blair William & Co. IL lifted its holdings in Moderna by 4.4% in the 4th quarter. Blair William & Co. IL now owns 13,887 shares of the company’s stock valued at $3,527,000 after acquiring an additional 590 shares during the last quarter. Clearstead Advisors LLC lifted its holdings in Moderna by 54.6% in the 4th quarter. Clearstead Advisors LLC now owns 354 shares of the company’s stock valued at $90,000 after acquiring an additional 125 shares during the last quarter. Finally, Mmbg Investment Advisors CO. acquired a new stake in Moderna in the 4th quarter valued at about $726,000. 60.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent research reports. SVB Leerink boosted their target price on shares of Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a research note on Monday, August 1st. Morgan Stanley lowered their price target on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a research report on Thursday, August 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “hold” rating to a “buy” rating and upped their price target for the stock from $155.00 to $165.00 in a research report on Wednesday, September 7th. Finally, Argus lowered their price target on shares of Moderna from $180.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, September 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $211.08.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Featured Articles

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.